Cargando…

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

Detalles Bibliográficos
Autores principales:	Shah, Urvi A., Whiting, Karissa, Devlin, Sean, Ershler, Rachel, Kanapuru, Bindu, Lee, David J., Tahri, Sabrin, Gwise, Thomas, Rustad, Even H., Mailankody, Sham, Lesokhin, Alexander M., Kazandjian, Dickran, Maura, Francesco, Auclair, Daniel, Birmann, Brenda M., Usmani, Saad Z., Gormley, Nicole, Marinac, Catherine R., Landgren, Ola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834289/ https://www.ncbi.nlm.nih.gov/pubmed/36631444 http://dx.doi.org/10.1038/s41408-022-00782-7

Ejemplares similares

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021)

Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement
por: Fernandes, Laura L., et al.
Publicado: (2021)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
por: Rustad, Even H., et al.
Publicado: (2021)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2019)

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2020)

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Nutrition perceptions, needs and practices among patients with plasma cell disorders
por: Malik, Maria A., et al.
Publicado: (2022)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
por: Oben, Bénedith, et al.
Publicado: (2021)

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
por: Korde, Neha, et al.
Publicado: (2021)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease
por: Hofmann, Jonathan N, et al.
Publicado: (2017)

Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment
por: Oganesyan, Artem, et al.
Publicado: (2022)

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2019)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2021)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Pre-Diagnosis Dietary Patterns and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study
por: Castro, Francesca, et al.
Publicado: (2023)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations
por: Maclachlan, Kylee H., et al.
Publicado: (2022)

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
por: Akhlaghi, T., et al.
Publicado: (2022)

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies
por: Mailankody, Sham, et al.
Publicado: (2016)

Dissecting racial disparities in multiple myeloma
por: Marinac, Catherine R., et al.
Publicado: (2020)

Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine
por: Prasad, Vinay, et al.
Publicado: (2015)

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
por: Anderson, Kenneth C., et al.
Publicado: (2021)

Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All
por: Lomas, Oliver C., et al.
Publicado: (2020)

Dietary intake is associated with risk of multiple myeloma and its precursor disease
por: Thordardottir, Marianna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0ij5k903tjmh3c2cnet3rsa8e9